These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 15285885)

  • 21. Direct measurement of intratumor dose-rate distributions in experimental xenografts treated with 90Y-labeled radioimmunotherapy.
    Mayer R; Dillehay LE; Shao Y; Zhang YG; Song S; Bartholomew RM; Mackenson DG; Williams JR
    Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):147-57. PubMed ID: 7721611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiation absorbed dose estimates for indium-111-labeled B72.3, an IgG antibody to ovarian and colorectal cancer: MIRD dose estimate report No. 18.
    Mardirossian G; Brill AB; Harwood SJ; Olsen J; Dwyer KA; Siegel JA
    J Nucl Med; 1998 Apr; 39(4):671-6. PubMed ID: 9544680
    [No Abstract]   [Full Text] [Related]  

  • 23. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry.
    Baechler S; Hobbs RF; Prideaux AR; Wahl RL; Sgouros G
    Med Phys; 2008 Mar; 35(3):1123-34. PubMed ID: 18404947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A theoretical radiobiological assessment of the influence of radionuclide half-life on tumor response in targeted radiotherapy when a constant kidney toxicity is maintained.
    Abou-Jaoudé W; Dale R
    Cancer Biother Radiopharm; 2004 Jun; 19(3):308-21. PubMed ID: 15285877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
    Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
    J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implementation and evaluation of patient-specific three-dimensional internal dosimetry.
    Kolbert KS; Sgouros G; Scott AM; Bronstein JE; Malane RA; Zhang J; Kalaigian H; McNamara S; Schwartz L; Larson SM
    J Nucl Med; 1997 Feb; 38(2):301-8. PubMed ID: 9025759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody.
    Breitz HB; Fisher DR; Wessels BW
    J Nucl Med; 1998 Oct; 39(10):1746-51. PubMed ID: 9776281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of systemic radiotherapy with I-131-labeled monoclonal antibody BW575/9 to external beam radiotherapy in human neuroblastoma xenografts.
    Sautter-Bihl ML; Wessely R; Bihl H
    Strahlenther Onkol; 1993 Oct; 169(10):595-600. PubMed ID: 8235984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft.
    Barendswaard EC; O'Donoghue JA; Larson SM; Tschmelitsch J; Welt S; Finn RD; Humm JL
    J Nucl Med; 1999 Oct; 40(10):1764-8. PubMed ID: 10520720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microdosimetric concepts in radioimmunotherapy.
    Humm JL; Roeske JC; Fisher DR; Chen GT
    Med Phys; 1993; 20(2 Pt 2):535-41. PubMed ID: 8492762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients?
    Konijnenberg MW
    Cancer Biother Radiopharm; 2003 Aug; 18(4):619-25. PubMed ID: 14503958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection.
    Flynn AA; Green AJ; Pedley RB; Boxer GM; Dearling J; Watson R; Boden R; Begent RH
    Cancer; 2002 Feb; 94(4 Suppl):1249-57. PubMed ID: 11877753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy.
    Griffith MH; Yorke ED; Wessels BW; DeNardo GL; Neacy WP
    J Nucl Med; 1988 Nov; 29(11):1795-809. PubMed ID: 3263479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies.
    Gestin JF; Loussouarn A; Bardiès M; Gautherot E; Gruaz-Guyon A; Saï-Maurel C; Barbet J; Curtet C; Chatal JF; Faivre-Chauvet A
    J Nucl Med; 2001 Jan; 42(1):146-53. PubMed ID: 11197965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radioimmunotherapy of solid cancers: A review.
    Kairemo KJ
    Acta Oncol; 1996; 35(3):343-55. PubMed ID: 8679266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3D calculation of absorbed dose for 131I-targeted radiotherapy: a Monte Carlo study.
    Saeedzadeh E; Sarkar S; Abbaspour Tehrani-Fard A; Ay MR; Khosravi HR; Loudos G
    Radiat Prot Dosimetry; 2012 Jul; 150(3):298-305. PubMed ID: 22069233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
    Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
    J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
    Barone R; Borson-Chazot F; Valkema R; Walrand S; Chauvin F; Gogou L; Kvols LK; Krenning EP; Jamar F; Pauwels S
    J Nucl Med; 2005 Jan; 46 Suppl 1():99S-106S. PubMed ID: 15653658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.